NEW: The long-awaited remdesivir data has arrived: nejm.org/doi/full/10.10…
"These preliminary findings support the use of remdesivir for patients who are hospitalized with Covid-19 and require supplemental oxygen therapy. However, given high mortality despite the use of remdesivir, it is clear that treatment with an antiviral drug alone is not..."
"...likely to be sufficient. Future strategies should evaluate antiviral agents in combination with other therapeutic approaches or combinations of antiviral agents to continue to improve patient outcomes in Covid-19."
Note: Remdesivir is intravenous; its use is necessarily limited. There’s a national shortage and some hospitals use lotteries to decide who gets it. We need additional studies to determine if it will be useful for patients with mild disease.
